Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of Intramuscular Pegaspargase (Hamsyl) of Gennova Biopharmaceuticals Ltd versus Intramuschlar Oncaspar in Pediatric patients with relapsed cased of Acute Lymphoblastic Leukemia

X
Trial Profile

A prospective, open label, randomized, active control, parallel design, comparative pharmacokinetics study of Intramuscular Pegaspargase (Hamsyl) of Gennova Biopharmaceuticals Ltd versus Intramuschlar Oncaspar in Pediatric patients with relapsed cased of Acute Lymphoblastic Leukemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegaspargase (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Pharmacokinetics
  • Sponsors Gennova Biopharmaceuticals
  • Most Recent Events

    • 26 Mar 2019 Status changed from not yet recruiting to completed.
    • 26 Aug 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top